Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GRAL vs GPCR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GRAL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)

GRAL Overall Winner 6-Pillar Tally: GRAL 3 – 2 GPCR (1 Tie) Matrix Metrics: GRAL 7 – 3 GPCR

As of Nov 16, 2026, GRAIL, Inc. (GRAL) is the stronger overall head-to-head candidate over Structure Therapeutics Inc. (GPCR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas GPCR carries 41.2/100 (SELL) at $18.57 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile GPCR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GRAL vs GPCR
GRAL NASDAQ Head-to-Head Winner
GRAIL, Inc. Common Stock
Services-Medical Laboratories
$105.60
-8.88% 1D
Market Cap $5.2B
TTM Revenue $167M
Forward P/E 1.1x
Beta / 30D Vol 3.09β · 99% Vol
Unified Composite Score
54.5 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.7 · SMA20: $132.32 · SMA50: $121.37
GPCR NASDAQ
Structure Therapeutics Inc. American Depositary Shares
Pharmaceutical Preparations
$18.57
-7.15% 1D
Market Cap $1.4B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.37β · 58% Vol
Unified Composite Score
41.2 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.2%), weak momentum, RSI 28
RSI-14: 28.4 · SMA20: $20.95 · SMA50: $27.31

6-Pillar Scorecard Institutional Category Breakdown (GRAL 3 – 2 GPCR)

Columns: Metric · GRAL · GPCR
1. Valuation Multiples GRAL
Forward P/E 1.1x N/M
Trailing P/E 1.1x N/M
PEG Ratio N/M N/M
EV / Revenue 31.6x N/M
2. Growth & Scale GRAL
Revenue Growth (YoY) +3.7% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $167M N/A
Market Cap $5.2B $1.4B
3. Profitability & Quality GPCR
Gross Margin 46.7% N/A
Operating Margin -332.0% 0.0%
Net Profit Margin -243.8% 0.0%
Return on Equity (ROE) -17.3% -20.2%
4. Balance Sheet & Cash Flow GRAL
Cash Generation (TTM) -$312M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $57M Net Debt (0.03x D/E) $21.41 Book/Sh · -20.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning GPCR
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 93.0% (53rd %ile) 120.4% (<1st %ile)
Put/Call OI Skew 0.81x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GRAL (7) vs GPCR (3)
Institutional Metric GRAL GPCR Criterion Row Edge
Market Capitalization
Scale
$5.2B $1.4B Larger Scale GRAL
Trailing P/E Ratio
Valuation
1.1x N/M Lower Multiple GRAL
Forward P/E Ratio
Valuation
1.1x N/M Lower Multiple GRAL
Revenue Growth (YoY)
Growth
+3.7% +0.0% Higher Growth GRAL
Operating Margin (TTM)
Profitability
-332.0% 0.0% Higher Margin GPCR
Net Profit Margin
Profitability
-243.8% 0.0% Higher Margin GPCR
Return on Equity (ROE)
Capital Efficiency
-17.3% -20.2% Higher ROE GRAL
52-Week Range Position
Momentum
51% ($42–$166) 0% ($18–$95) Stronger Trend GRAL
Beta / 30D Volatility
Risk Regime
3.09β · 99% Vol 1.37β · 58% Vol Lower Realized Risk GPCR
Unified Institutional Score
Composite Signal
54.5 / 100 (HOLD) 41.2 / 100 (SELL) Higher Composite GRAL
Trailing 12M Revenue (USD)
Operating Scale
$167M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 31.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$312M ($57M Net Debt (0.03x D/E)) N/A ($21.41 Book/Sh · -20.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GRAL +1.55 pp
GRAL: -10.36% · GPCR: -11.91%
3M Horizon GRAL +116.42 pp
GRAL: +50.96% · GPCR: -65.46%
6M Horizon GRAL +129.03 pp
GRAL: +77.03% · GPCR: -52.0%
1Y Horizon GRAL +73.86 pp
GRAL: +26.92% · GPCR: -46.94%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GRAL vs GPCR. Trailing 12-month operating profitability (GRAL -332.0% vs GPCR 0.0%) and valuation multiples (GRAL 1.1x vs GPCR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

GRAL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$167M
Gross Margin46.7%
Op. Margin-332.0%
ROE / Fwd P/E-17.3% · 1.1x
GPCR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-20.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GRAL BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 93.0%
IV Percentile 53rd %ile
Put/Call OI Skew 0.81x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact GRAL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GPCR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 120.4%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GPCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GRAL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.2B market capitalization and -332.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GPCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GRAL vs GPCR Key Questions & Quantitative Answers

As of Nov 16, 2026, GRAIL, Inc. (GRAL) is the stronger overall head-to-head candidate over Structure Therapeutics Inc. (GPCR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas GPCR carries 41.2/100 (SELL) at $18.57 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile GPCR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GRAL leads the Growth & Scale pillar: GRAL posts +3.7% YoY revenue growth and +0.0% YoY earnings growth on $167M TTM revenue (46.7% gross margin, -332.0% operating margin), compared with GPCR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, GRAL generates $167M in USD-normalized revenue versus N/A for GPCR. In operating R&D and SG&A reinvestment, GRAL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GPCR.

GRAL screens cheaper on headline valuation multiples. GRAL trades at 1.1x Forward P/E, 1.1x Trailing P/E, N/M PEG, and 31.6x EV/Revenue (unreported FCF margin), whereas GPCR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GRAL (-17.3% ROE) versus GPCR (-20.2% ROE) capital efficiency.

In options market volatility and institutional positioning, GRAL carries 93.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 99% Vol realized risk). By comparison, GPCR carries 120.4% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.37β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.